Literature DB >> 26683181

Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor.

Tomohiro Osaki1, Cai-Xia Wang1, Taro Tachibana1,2, Masayuki Azuma1, Masaya Kitamura1, Takeshi Nakanishi1.   

Abstract

Overexpression of the epidermal growth factor receptor (EGFR) gene and dysregulation of EGFR signaling are observed in various cancer cells, and EGFR is a validated target for cancer therapy. In the present study, we report on the generation of two rat anti-EGFR antibodies (clones 2C2D3 and 4H7F4) by using the rat lymph node method. Flow cytometric analysis and immunofluorescence showed that both antibodies specifically bound to EGFR on the surface of cancer cells. Competitive analysis demonstrated that the epitope of each antibody had no overlap with that of the therapeutic anti-EGFR antibody cetuximab. These results suggest that 2C2D3 and 4H7F4 are potentially useful in EGFR-targeted cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26683181      PMCID: PMC4685498          DOI: 10.1089/mab.2015.0034

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN: 2167-9436


  16 in total

1.  Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5.

Authors:  J Miyazaki; S Takaki; K Araki; F Tashiro; A Tominaga; K Takatsu; K Yamamura
Journal:  Gene       Date:  1989-07-15       Impact factor: 3.688

2.  Epidermal growth factor receptor downregulation by small heterodimeric binding proteins.

Authors:  Benjamin J Hackel; Jason R Neil; Forest M White; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2011-12-09       Impact factor: 1.650

Review 3.  Epidermal growth factor receptor (EGFR) signaling in cancer.

Authors:  Nicola Normanno; Antonella De Luca; Caterina Bianco; Luigi Strizzi; Mario Mancino; Monica R Maiello; Adele Carotenuto; Gianfranco De Feo; Francesco Caponigro; David S Salomon
Journal:  Gene       Date:  2005-12-27       Impact factor: 3.688

4.  Resistance to EGFR-targeted therapy: a family affair.

Authors:  Gregory Vlacich; Robert J Coffey
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

5.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

Review 6.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

7.  Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.

Authors:  Ykelien L Boersma; Ginger Chao; Daniel Steiner; K Dane Wittrup; Andreas Plückthun
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

Review 8.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

9.  A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.

Authors:  Rob C Roovers; Maria J W D Vosjan; Toon Laeremans; Rachid el Khoulati; Renée C G de Bruin; Kathryn M Ferguson; Arie J Verkleij; Guus A M S van Dongen; Paul M P van Bergen en Henegouwen
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

10.  A novel method of preparing rat-monoclonal antibody-producing hybridomas by using rat medial iliac lymph node cells.

Authors:  Y Kishiro; M Kagawa; I Naito; Y Sado
Journal:  Cell Struct Funct       Date:  1995-04       Impact factor: 2.212

View more
  1 in total

1.  A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats.

Authors:  Francesco Nannini; Farhaan Parekh; Patrycja Wawrzyniecka; Leila Mekkaoui; Matteo Righi; Fatemeh V Dastjerdi; Jenny Yeung; Claire Roddie; Yuchen Bai; Biao Ma; Mathieu Ferrari; Shimobi Onuoha; Kerry Chester; Martin Pule
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.